Učitavanje...
Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...
Spremljeno u:
| Izdano u: | eLife |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
eLife Sciences Publications, Ltd
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8064747/ https://ncbi.nlm.nih.gov/pubmed/33830018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.68808 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|